27/06/2025
IMPORTANT PATIENT INFORMATION REGARDING WEIGHT LOSS INJECTIONS
Eligibility depends on your BMI, ethnic background, and the presence of certain health conditions (known as comorbidities). The rollout is happening in three cohorts:
Cohort 1 – From 23 June 2025
• BMI of 40 or higher, or 37.5 or higher if you are from a South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean background
• Plus at least 4 of the following conditions:
High blood pressure (on treatment)
High cholesterol (on statins or similar medication)
Obstructive sleep apnoea
Cardiovascular disease
Type 2 diabetes
Cohort 2 – From June 2026 (exact date to be confirmed)
• BMI of 35 or higher, or 32.5 or higher if from an eligible ethnic background (as above)
• Plus at least 4 of the same listed conditions as above
Cohort 3 – From April 2027 (exact date to be confirmed)
• BMI of 40 or higher, or 37.5 or higher if from an eligible ethnic background
• Plus at least 3 of the same listed conditions as above
Please Note
• Responsibility for this roll out has been delegated to ICBs and we await further details from NHS Somerset to be able to deliver to cohort one eligible patients. Until such time as this is confirmed, we are unable to prescribe the medication;
• We are unable to prescribe Mounjaro or similar medications for weight loss outside of the below NHS guidelines; and
• If you are not eligible, we encourage all patients to continue engaging with existing weight management support, including the NHS 12 week weight loss plan - https://www.nhs.uk/better-health/lose-weight/
We appreciate your understanding and cooperation.
